Antimicrobial Coating for Biofilm Inhibition

描述（由申请人提供）：念珠菌是第三大导致 导管相关的医院内血流感染。留置器械具有 已显示支持念珠菌的定殖和生物膜形成。 静脉输液管是最常见的留置器械， 念珠菌血症的最常见原因。一旦念珠菌生物膜在体内形成， 几乎总是需要支持生物膜生长的基质来消除感染。不幸的是，在许多情况下， 由于患者状况恶化、解剖位置或 基础疾病。 该项目的目标是将抗真菌剂纳入独特的， 获得专利的配方，为医疗器械创造耐腐蚀的涂层 梭白色念珠菌。一种涂层和抗真菌输送系统，可以延长 时间和/或增加递送速率并实现更高浓度的 抗真菌剂对C.白色念珠菌易感部位会有巨大的 相对于全身和无效的局部途径的治疗优势 交付.为了证明这种方法的可行性， 是优化涂层配方，用作短期抗真菌剂， 用于医疗器械的涂层，评价涂层的抗真菌活性， 体外，并在家兔中进行肌内植入研究。 拟议的商业应用：白色念珠菌是迄今为止最常见的分离出的人类支原体。 大量的免疫抑制患者使用留置装置，加上治疗C。与白色念珠菌有关的感染是寻求替代疗法的理由。

Description(provided by applicant): Candida is the third leading cause of catheter-related nosocomial bloodstream infections. Indwelling devices have been shown to support colonization and biofilm formulation by Candida. Intravenous lines are the most frequent indwelling device and are the single most common cause of candidemia. Once a Candida biofilm forms in vivo, removal of the substrate that is supporting the biofilm growth is almost always required to eliminate the infection. Unfortunately, in many instances removal is impossible due to deteriorated patient condition, anatomical location, or underlying disease. The goal of this project is to incorporate an antifungal agent into unique, patented formulations to create a coating for medical devices that is resistant to C. albicans. A coating and antifungal delivery system that could extend the time and/or increase the rate of delivery and achieve a higher concentration of antifungal agents to a C. albicans-susceptible site would have enormous therapeutic advantages over systemic and inefficacious topical routes of delivery. To demonstrate the feasibility of this approach, the specific aims are to optimize the coating formulation for use as short-term antifungal coatings for medical devices, evaluate the coatings for antifungal activity in vitro, and to perform an intramuscular implantation study in rabbits. PROPOSED COMMERCIAL APPLICATION: Candida albicans is by far the most frequently isolated human mycotic agent. The large number of immunosuppressed patients with indwelling devices combined with the extensive social and economic costs associated with treating C. albicans-related infections serve as justification for the pursuit of alternative therapies.